PhRMA to Federal Appeals Court: Arkansas Enforcing 340B Contract Pharmacy Law; Seventh Drugmaker Sues Over IRA

Eighth Circuit Court
PhRMA filed a citation to notify the U.S. Eighth Circuit Court of Appeals in St. Louis that Arkansas is enforcing its 340B contract pharmacy law.
The drug industry group challenging the legality of Arkansas’ 340B contract pharmacy law, notified a federal appeals court that the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Tolmar Providing Refunds for Five Years of 340B Overcharges

Drugmaker Tolmar said it will refund 340B covered entities for overcharges on certain generic dermatologic products.
Drug manufacturer Tolmar recently said it plans refunds to 340B covered entities for overcharges on seven generic dermatologic products purchased [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

UCB Tightens 340B Contract Pharmacy Restrictions for Hospitals

UCB signage and building
UCB announced it will tighten its existing 340B contract restrictions on hospitals beginning Oct. 2.
Belgium drug maker UCB will add restrictions on 340B contract pharmacy use for hospitals starting Oct. 2, according to a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

EMD Serono Extends Hospital 340B Contract Pharmacy Conditions to All Products

EMD Serono wordmark on building
Beginning Oct. 1, EMD Serono will extend its contract pharmacy restrictions to all 340B covered entities.
Drug manufacturer EMD Serono (EMDS) today announced 340B contract pharmacy restrictions for hospitals will expand Oct. 1 to all of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Arkansas Initiates First-in-the-Nation Enforcement of 340B Contract Pharmacy Law

Arkansas Insurance Department office sign
The Arkansas Insurance Department will imminently enforce a state 340B contract pharmacy law following a key federal appeals court decision.
The Arkansas Insurance Department (AID) has formally notified at least four drugmakers that they are in potential violation of a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Boehringer Ingelheim Sues to Block Medicare Price Negotiations

Boehringer Ingelheim headquarters
Boehringer Ingelheim sued the federal government to block Medicare price negotiations shortly before its diabetes drug was picked for negotiations.
Drug maker Boehringer Ingelheim (BI) sued the federal government to block Medicare price negotiations shortly before the Department of Health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies

Sanofi outdoor building sign
Changes to Sanofi's 340B drug pricing conditions may eliminate 340B discounts for health centers using multiple contract pharmacies within a chain.
Recent apparent changes to 340B drug pricing conditions by drug manufacturer Sanofi may eliminate 340B discounts for health centers using [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Lawmaker Sponsoring 340B Transparency Bill Honored by PhRMA-Provider Group

Buschon ASAP 340B award
Rep. Larry Bucshon (R-Indiana) received the "Saving America’s 340B Program Leadership Award" award from ASAP 340B.
The congressional sponsor of legislation that would require hospitals and potentially other covered entities to publicly report their 340B revenue, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HHS Announces First 10 Drugs Eligible for Medicare Price Negotiations

CMS headquarters
CMS issued the final rule to implement a $9 billion lump sum payment to 340B hospitals for previous illegal cuts between 2018 and 2021.
The Department of Health and Human Services (HHS) today announced the first 10 prescription drugs eligible for Medicare price negotiations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Drugmaker AstraZeneca sued the federal government to block Medicare drug price negotiations on Friday, just days before the government announced [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live